Pcn77 - Budget Impact Analysis of Blinatumomab for the Treatment of Pediatric Patients With Philadelphia Negative Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Mexico

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.159
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn71 - Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2019English

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Advances in Therapy
MedicinePharmacology
2019English

Pcn142 - Cost-Effectiveness Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

FDA Approval: Blinatumomab for Patients With B-Cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission With Minimal Residual Disease

Clinical Cancer Research
Cancer ResearchOncology
2019English

Correlates of Resistance and Relapse During Blinatumomab Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2017English

Pcn170 - Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Canadian Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Concurrent Use of Blinatumomab and Donor Lymphocyte Infusion (DLI) for Treatment of Relapsed Precursor B Cell Acute Lymphoblastic Leukemia (Pre B ALL) After Allogeneic Hematopoietic Cell Transplant (HCT)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy